Replies to post #146025 on Biotech Values

[DewDiligence]

De novo claims construction is apropos to appeal of Copaxone patent case:

http://arstechnica.com/tech-policy/2013/03/federal-judges-get-no-respect-in-patent-appeals-but-that-may-change

This is one of the main reasons MNTA management likes the odds for reversal of the District Court ruling.